Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BaseLaunch adds new Phase II partner
September 2020
SHARING OPTIONS:

BASEL, Switzerland—Biotech venture accelerator and incubator BaseLaunch announced in July that Bridge Biotherapeutics Inc. had joined as a partner in BaseLaunch Phase II, marking the first Asia Pacific company to partner with BaseLaunch. Bridge Biotherapeutics joins the ranks of Roche, BB Pureos Bioventures and Roivant Sciences as part of BaseLaunch’s initiative to support the next generation of biotech companies. For Phase II, BaseLaunch is increasing the funding per venture to a maximum of $500,000, up from $250,000.
 
“We are very excited to be expanding our partnership into Asia Pacific with Bridge Biotherapeutics, an entrepreneurially operated and mission-driven biotech company, to together identify, nurture and grow transformative therapeutic ventures, both in Europe and beyond,” said Stephan Emmerth, director of business development and operations at BaseLaunch. “Bridge’s commitment to BaseLaunch further highlights the level of interest from leading and highly innovative corporate partners in the global biopharma community.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.